SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma

Carcinogenesis

Volumn 33, Issue 8, 2012, Pages 1581-1588

  Hu, Liang ^a,b,c   Liu, Ming ^c   Chen, Leilei ^c,d   Chan, Tim Hon Man ^c,d   Wang, Jian ^c   Huo, Ke Ke ^e   Zheng, Bo Jian ^c   Xie, Dan ^f   Guan, Xin Yuan ^c,d,f  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b National Engineering Research Center of Human Stem Cells   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d THE UNIVERSITY OF HONG KONG   (Hong Kong)

^e FUDAN UNIVERSITY   (China)

^f SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; PROTEIN P53; PROTEIN PIRH2; SCYL1 BINDING PROTEIN 1; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL NUCLEUS; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; FLOW CYTOMETRY; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; PROTEOLYSIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84865326385     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs162     Document Type: Article

References (29)

1. Beitel,L.K. et al. (2002) Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity. J. Mol. Endocrinol., 29, 41-60.
2. Leng,R.P. et al. (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell, 112, 779-791.
3. Li,Q. et al. (2009) Axin determines cell fate by controlling the p53 activation threshold after DNA damage. Nat. Cell Biol., 11, 1128-1134.
4. Duan,S. et al. (2007) Phosphorylation of Pirh2 by calmodulin-dependent kinase II impairs its ability to ubiquitinate p53. EMBO J., 26, 3062-3074.
5. Logan,I.R. et al. (2004) Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome. J. Biol. Chem., 279, 11696-11704.
6. Zheng,G. et al. (2007) PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53. Biochem. Biophys. Res. Commun., 364, 344-350.
7. Cheng,S.H. et al. (2006) Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J. Clin. Oncol., 24, 4594-4602.
8. Nuyten,D.S.A. et al. (2008) Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity. Semin. Radiat. Oncol., 18, 105-114.
9. Duan W. et al. (2004) Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J. Nation. Cancer Inst., 96, 1718-1721.
10. Shimada M. et al. (2009) High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers. Cancer Sci., 100, 866-872.
11. Wang,X.M. et al. (2009) p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer, 115, 4554-4563.
12. Zhang L. et al. (2005) A new human gene hNTKL-BP1 interacts with hPirh2. Biochem. Biophys. Res. Commun., 330, 293-297.
13. Ma N.F. et al. (2008) Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology, 47, 503-510.
14. Chen L. et al. (2009) Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-Like (CHD1L) gene suppresses the nucleus-tomitochondria translocation of Nur77 to sustain hepatocellular carcinoma cell survival. Hepatology, 50, 122-129.
15. Chen L. et al. (2010) CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J. Clin. Invest., 120, 1178-1191.
16. Yan,J. et al. (2010) A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination. Febs Lett., 584, 3275-3278.
17. Momand,J. et al. (1992) The Mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
18. Yan,J. et al. (2010) Overexpression of SCYL1-BP1 stabilizes functional p53 by suppressing MDM2-mediated ubiquitination. Febs Lett., 584, 4319-4324.
19. Fu L. et al. (2007) Characterization of a novel tumor-suppressor gene PLC delta 1 at 3p22 in Esophageal squamous cell carcinoma. Cancer Res., 67, 10720-10726.
20. Wang Y. et al. (2002) Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma - a broad survey using high-throughput tissue microarray. Cancer, 95, 2346-2352.
21. O'Keefe,K. et al. (2003) Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol. Cell. Biol., 23, 6396-6405.
22. Logan,I.R. et al. (2004) Control of human PIRH2 protein stability - involvement of TIP60 and the proteasome. J. Biol. Chem., 279, 11696-11704.
23. Chen,M.Z. et al. (2005) Inhibition of ubiquitination and stabilization of human ubiquitin E3 ligase PIRH2 by measles virus phosphoprotein. J. Virol., 79, 11824-11836.
24. Hennies H.C. et al. (2009) Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a novel RAB-6 interacting golgin. Bone, 44, S232-S232.
25. Hattori T. et al. (2007) Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27(Kip1). Cancer Res., 67, 10789-10795.
26. Huang,X. et al. (2011) Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation. Human Pathol., 42, 507-515.
27. Brooks,C.L. et al. (2006) p53 ubiquitination: Mdm2 and beyond. Mol. Cell, 21, 307-315.
28. Martinez,J. et al. (1991) Cellular-localization and cell-cycle regulation by a temperature-sensitive p53-protein. Genes Dev., 5, 151-159.
29. Polyak,K. et al. (1994) Cloning of p27(Kip1), a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66.